



DOSING REAGILA®



Re-embrace life

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

COD: 300090/A19. Submitted to AIFA on 26/07/2019

Reagila is indicated for the treatment of schizophrenia in adult patients¹.

DOSAGE STRENGTHS



1.5 mg



3 mg



4.5 mg



6 mg

Not actual size

Available in **4 dosage strengths**: 1.5, 3, 4.5, 6 mg¹.

POSODOLOGY



To be taken **once daily** with or without food, at any time during the day¹.

Reagila is intended as monotherapy for the treatment of schizophrenia; this also includes treatment of negative symptoms of schizophrenia¹.

DOSING AND UP-TITRATION



The **starting dose** of Reagila is 1.5 mg¹.


When introducing Reagila to **untreated patients**, **start with the dose of 1.5 mg** and **slowly escalate the dose** in 1.5 mg increments to a **maximum dose of 6 mg/day**, if needed. The lowest effective dose should be maintained¹.

Fast up-titration: dose escalation scheme in clinical trials².

	Day 1	Day 2	Day 3	Day 4
Durgam, 2014	1.5 mg	3.0 mg	4.5 mg	-
Durgam, 2015	1.5 mg	3.0 mg	4.5 mg	6.0 mg
Kane, 2015	1.5 mg	3.0 mg	(3.0 mg)	6.0 mg

6 week acute studies with cariprazine vs placebo

SWITCHING TO CARIPRAZINE



When switching from other antipsychotics to cariprazine, gradual cross-titration should be considered, with gradual discontinuation of the previous treatment within one week while cariprazine treatment is initiated within that same week¹.



For some drugs (such as asenapine, olanzapine, quetiapine and clozapine) slower down-titration is advised (3-4 weeks) to let patients adapt to the withdrawal of cholinergic, histaminergic and alpha-1 adrenergic receptor blockade³.

SWITCHING FROM CARIPRAZINE



When switching to other antipsychotics from cariprazine, no gradual cross-titration is needed¹. The new antipsychotic should be initiated in its lower dose while cariprazine is discontinued. Due to the long half-life of Reagila (50% decline in ~1 week, greater than 90% decline in ~3 weeks) the dose can be stopped at once¹.

1. Reagila summary of product characteristics 2. Durgam S. Schizophr Res. 2014; Durgam S. J Clin Psychiatry. 2015; Kane JM. J Clin Psychopharmacol. 2015 3. Stahl S, Stahl's Essential Psychopharmacology Prescriber's Guide, 6th edition, Cambridge University Press, 2017